MedTrace Logo

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

NCT05125068 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-03-26

No results posted yet for this study

Summary

This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.

Conditions

Interventions

DRUG

AT-1501

AT-1501 monoclonal antibody targeting CD40L given as an IV infusion

Sponsors & Collaborators

  • Eledon Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-21
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • Australia
  • Croatia
  • Malaysia
  • New Zealand
  • Philippines
  • Poland
  • Spain
  • Sri Lanka
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05125068 on ClinicalTrials.gov